Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance. “ Geographic atrophy is a progressive disease associated ...

OLN324 shows comparable vision gains, potential durability advantage vs faricimab in phase 1b wAMD, DME study ...

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs). At the Retina World Congress 2025 in Lauderdale, ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their approaches to dosing recommendations for faricimab in the treatment of neovascular AMD.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience. Affecting more than 21 million people globally, DME ...

Altris also has advanced AI models to enable vendor-neutral retina layers segmentation as well as detection and visualization of more than 70 retina conditions such as dry and wet age-related macular ...

This phase 2b study (ASPIRE) is currently underway. UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual ...

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials. Breye Therapeutics announced the successful ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...